{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:50:07Z","timestamp":1792799407480,"version":"4.5.0"},"reference-count":42,"publisher":"American Association for Cancer Research (AACR)","issue":"4","funder":[{"name":"V Foundation Clinical Scholar"},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"crossref","award":["AWD00005712"],"award-info":[{"award-number":["AWD00005712"]}],"id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Cancer Institute","award":["CA009666"],"award-info":[{"award-number":["CA009666"]}]},{"name":"National Cancer Institute","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}]},{"name":"Leukemia and Lymphoma Society","id":[{"id":"https:\/\/ror.org\/04m0xav37","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"crossref","award":["CA10063"],"award-info":[{"award-number":["CA10063"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The safety and efficacy of combining the isocitrate dehydrogenase-1 (IDH1) inhibitor ivosidenib (IVO) with the BCL2 inhibitor venetoclax (VEN; IVO + VEN) \u00b1 azacitidine (AZA; IVO + VEN + AZA) were evaluated in four cohorts of patients with IDH1-mutated myeloid malignancies (n = 31). Most (91%) adverse events were grade 1 or 2. The maximal tolerated dose was not reached. Composite complete remission with IVO + VEN + AZA versus IVO + VEN was 90% versus 83%. Among measurable residual disease (MRD)-evaluable patients (N = 16), 63% attained MRD-negative remissions; IDH1 mutation clearance occurred in 64% of patients receiving \u22655 treatment cycles (N = 14). Median event-free survival and overall survival were 36 [94% CI, 23\u2013not reached (NR)] and 42 (95% CI, 42-NR) months. Patients with signaling gene mutations appeared to particularly benefit from the triplet regimen. Longitudinal single-cell proteogenomic analyses linked cooccurring mutations, antiapoptotic protein expression, and cell maturation to therapeutic sensitivity of IDH1-mutated clones. No IDH isoform switching or second-site IDH1 mutations were observed, indicating combination therapy may overcome established resistance pathways to single-agent IVO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>IVO + VEN + AZA is safe and active in patients with IDH1-mutated myeloid malignancies. Combination therapy appears to overcome resistance mechanisms observed with single-agent IDH-inhibitor use, with high MRD-negative remission rates. Single-cell DNA \u00b1 protein and time-of-flight mass-cytometry analysis revealed complex resistance mechanisms at relapse, highlighting key pathways for future therapeutic intervention.<\/jats:p>\n                    <jats:p>Watch the interview with Courtney D. DiNardo, MD, MSCE, recipient of the 2025 Blood Cancer Discovery Award for Outstanding Journal Article: https:\/\/vimeo.com\/1100470320<\/jats:p>\n                    <jats:p>This article is highlighted in the In This Issue feature, p. 247<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-22-0205","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T10:09:48Z","timestamp":1682590188000},"page":"276-293","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":127,"title":["A Phase Ib\/II Study of Ivosidenib with Venetoclax \u00b1 Azacitidine in\n                    <i>IDH1<\/i>\n                    -Mutated Myeloid Malignancies"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8506-0624","authenticated-orcid":false,"given":"Curtis A.","family":"Lachowiez","sequence":"first","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[{"name":"2The University of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2207-9584","authenticated-orcid":false,"given":"Zhihong","family":"Zeng","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3790-4364","authenticated-orcid":false,"given":"Tomoyuki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8364-7971","authenticated-orcid":false,"given":"Yi June","family":"Kim","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7167-895X","authenticated-orcid":false,"given":"Hidetaka","family":"Uryu","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3377-1170","authenticated-orcid":false,"given":"Sven","family":"Turkalj","sequence":"additional","affiliation":[{"name":"3MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom."},{"name":"4Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom."},{"name":"5Oxford Centre for Haematology, NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5776-5085","authenticated-orcid":false,"given":"Niels Asger","family":"Jakobsen","sequence":"additional","affiliation":[{"name":"3MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom."},{"name":"4Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom."},{"name":"5Oxford Centre for Haematology, NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-4529","authenticated-orcid":false,"given":"Marlise R.","family":"Luskin","sequence":"additional","affiliation":[{"name":"6Dana-Farber Cancer Institute, Leukemia Program, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6763-9736","authenticated-orcid":false,"given":"Dzifa Y.","family":"Duose","sequence":"additional","affiliation":[{"name":"7The University of Texas MD Anderson Cancer Center, Department of Translational Molecular Pathology, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3041-8582","authenticated-orcid":false,"given":"Rebecca S.S.","family":"Tidwell","sequence":"additional","affiliation":[{"name":"8The University of Texas MD Anderson Cancer Center, Department of Biostatistics, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7679-6453","authenticated-orcid":false,"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6624-4196","authenticated-orcid":false,"given":"Lucia","family":"Masarova","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0565-1077","authenticated-orcid":false,"given":"George D.","family":"Tippett","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-5712","authenticated-orcid":false,"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias J.","family":"Jabbour","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2118-6302","authenticated-orcid":false,"given":"Jacqueline S.","family":"Garcia","sequence":"additional","affiliation":[{"name":"6Dana-Farber Cancer Institute, Leukemia Program, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3931-0914","authenticated-orcid":false,"given":"Paresh","family":"Vyas","sequence":"additional","affiliation":[{"name":"3MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom."},{"name":"4Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom."},{"name":"5Oxford Centre for Haematology, NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8027-9659","authenticated-orcid":false,"given":"Koichi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"2025112416574776700_bib1","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1038\/s41467-020-19119-8","article-title":"Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics","volume":"11","author":"Morita","year":"2020","journal-title":"Nat Commun"},{"key":"2025112416574776700_bib2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"key":"2025112416574776700_bib3","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"2025112416574776700_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41571-018-0156-2","article-title":"Advances in patient care through increasingly individualized therapy","volume":"16","author":"DiNardo","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2025112416574776700_bib5","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025112416574776700_bib6","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.24072","article-title":"Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML","volume":"90","author":"DiNardo","year":"2015","journal-title":"Am J Hematol"},{"key":"2025112416574776700_bib7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"2025112416574776700_bib8","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1182\/blood-2013-03-493197","article-title":"Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia","volume":"121","author":"DiNardo","year":"2013","journal-title":"Blood"},{"key":"2025112416574776700_bib9","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/s41375-021-01476-y","article-title":"Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells","volume":"36","author":"Wilson","year":"2022","journal-title":"Leukemia"},{"key":"2025112416574776700_bib10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"2025112416574776700_bib11","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"2025112416574776700_bib12","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41467-021-22874-x","article-title":"Leukemia stemness and cooccurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"2025112416574776700_bib13","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","article-title":"Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML","volume":"4","author":"Choe","year":"2020","journal-title":"Blood Adv"},{"key":"2025112416574776700_bib14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat Med"},{"key":"2025112416574776700_bib15","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"key":"2025112416574776700_bib16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"2025112416574776700_bib17","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025112416574776700_bib18","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"2025112416574776700_bib19","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"key":"2025112416574776700_bib20","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41375-021-01468-y","article-title":"Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia","volume":"36","author":"Cathelin","year":"2022","journal-title":"Leukemia"},{"key":"2025112416574776700_bib21","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"2025112416574776700_bib22","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/ajh.26314","article-title":"Development of TP53 mutations over the course of therapy for acute myeloid leukemia","volume":"96","author":"Alwash","year":"2021","journal-title":"Am J Hematol"},{"key":"2025112416574776700_bib23","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood.2020010167","article-title":"Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias","volume":"137","author":"Thijssen","year":"2021","journal-title":"Blood"},{"key":"2025112416574776700_bib24","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic Subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"key":"2025112416574776700_bib25","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood.2020006343","article-title":"CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues","volume":"138","author":"Yu","year":"2021","journal-title":"Blood"},{"key":"2025112416574776700_bib26","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025112416574776700_bib27","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/s41467-021-21233-0","article-title":"Biological and therapeutic implications of a unique subtype of NPM1 mutated AML","volume":"12","author":"Mer","year":"2021","journal-title":"Nat Commun"},{"key":"2025112416574776700_bib28","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-018-0115-6","article-title":"Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib","volume":"24","author":"Quek","year":"2018","journal-title":"Nat Med"},{"key":"2025112416574776700_bib29","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","article-title":"A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia","volume":"28","author":"Zeng","year":"2022","journal-title":"Nat Med"},{"key":"2025112416574776700_bib30","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","article-title":"Integrative analysis of drug response and clinical outcome in acute myeloid leukemia","volume":"40","author":"Bottomly","year":"2022","journal-title":"Cancer Cell"},{"key":"2025112416574776700_bib31","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanm\u00e4ki","year":"2020","journal-title":"Haematologica"},{"key":"2025112416574776700_bib32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13039-016-0275-3","article-title":"Sex chromosome loss after allogeneic hematopoietic stem cell transplant in patients with hematologic neoplasms: a diagnostic dilemma for clinical cytogeneticists","volume":"9","author":"Tang","year":"2016","journal-title":"Mol Cytogenet"},{"key":"2025112416574776700_bib33","first-page":"149","volume-title":"An international system for human cytogenomic nomenclature","author":"McGowan-Jordan","year":"2016"},{"key":"2025112416574776700_bib34","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.cll.2017.07.004","article-title":"How do we use multicolor flow cytometry to detect minimal residual disease in acute myeloid leukemia?","volume":"37","author":"Xu","year":"2017","journal-title":"Clin Lab Med"},{"key":"2025112416574776700_bib35","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025112416574776700_bib36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3324\/haematol.2018.191148","article-title":"Persistent IDH1\/2 mutations in remission can predict relapse in patients with acute myeloid leukemia","volume":"104","author":"Ok","year":"2019","journal-title":"Haematologica"},{"key":"2025112416574776700_bib37","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"2025112416574776700_bib38","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2307\/3315916","article-title":"Confidence curves and improved exact confidence intervals for discrete distributions","volume":"28","author":"Blaker","year":"2000","journal-title":"Can J Stat"},{"key":"2025112416574776700_bib39","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cyto.a.22628","article-title":"Single-cell mass cytometry reveals intracellular survival\/proliferative signaling in FLT3-ITD-mutated AML stem\/progenitor cells","volume":"87","author":"Han","year":"2015","journal-title":"Cytometry A"},{"key":"2025112416574776700_bib40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-1-4939-7142-8_5","article-title":"Single-cell mass cytometry of acute myeloid leukemia and leukemia stem\/progenitor cells","volume":"1633","author":"Zeng","year":"2017","journal-title":"Methods Mol Biol"},{"key":"2025112416574776700_bib41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nbt.4314","article-title":"Dimensionality reduction for visualizing single-cell data using UMAP","volume":"37","author":"Becht","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2025112416574776700_bib42","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data","volume":"87","author":"Van Gassen","year":"2015","journal-title":"Cytometry Part A"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-22-0205\/3326800\/bcd-22-0205.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-22-0205\/3339852\/bcd-22-0205.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/4\/4\/276\/3343530\/276.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/4\/4\/276\/3343530\/276.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T21:58:02Z","timestamp":1764021482000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/4\/4\/276\/727507\/A-Phase-Ib-II-Study-of-Ivosidenib-with-Venetoclax"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,26]]},"published-print":{"date-parts":[[2023,7,5]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-22-0205","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.23503815","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.23627525.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27024929","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27024929.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.23503815.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.23503818.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.29618997","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.23627522","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27024932.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30698680","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.23503818","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30698677","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.23627525","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.23627522.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27024932","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.29619000","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.23627522.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.23503815.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.23503818.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.23627525","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.23503815","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.6692454.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.23627525.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.23503818","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.6692454","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.6692454.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.23627522","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]}}}